Delta Lloyd Asset Management N.V. bought a new stake in shares of Humana Inc. (NYSE:HUM) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 22,637 shares of the insurance provider’s stock, valued at approximately $5,447,000.
Several other large investors also recently made changes to their positions in the stock. Swiss National Bank raised its holdings in shares of Humana by 2.9% during the 2nd quarter. Swiss National Bank now owns 622,826 shares of the insurance provider’s stock valued at $149,864,000 after buying an additional 17,800 shares during the period. Pacad Investment Ltd. purchased a new stake in shares of Humana during the 2nd quarter valued at about $1,372,000. OZ Management LP raised its holdings in shares of Humana by 4.9% during the 2nd quarter. OZ Management LP now owns 667,478 shares of the insurance provider’s stock valued at $160,608,000 after buying an additional 30,927 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Humana by 4.4% during the 2nd quarter. Principal Financial Group Inc. now owns 349,877 shares of the insurance provider’s stock valued at $84,188,000 after buying an additional 14,732 shares during the period. Finally, DSAM Partners London Ltd raised its holdings in shares of Humana by 0.5% during the 2nd quarter. DSAM Partners London Ltd now owns 45,948 shares of the insurance provider’s stock valued at $11,056,000 after buying an additional 207 shares during the period. Institutional investors and hedge funds own 95.14% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://ledgergazette.com/2017/09/17/delta-lloyd-asset-management-n-v-purchases-new-stake-in-humana-inc-hum.html.
Several equities research analysts recently commented on the company. UBS AG reiterated a “neutral” rating and set a $237.00 target price (up from $205.00) on shares of Humana in a report on Wednesday, June 28th. BidaskClub upgraded Humana from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Morgan Stanley raised their target price on Humana from $269.00 to $276.00 and gave the company an “overweight” rating in a report on Thursday, August 17th. Zacks Investment Research downgraded Humana from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $223.00 price objective (up from $200.00) on shares of Humana in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company. Humana currently has a consensus rating of “Buy” and an average price target of $244.35.
Humana Inc. (NYSE HUM) opened at 249.28 on Friday. The company’s 50-day moving average price is $250.25 and its 200-day moving average price is $231.50. Humana Inc. has a 52-week low of $163.50 and a 52-week high of $259.76. The firm has a market cap of $36.03 billion, a price-to-earnings ratio of 20.51 and a beta of 0.87.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The business had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. During the same period in the prior year, the firm posted $2.30 EPS. Analysts predict that Humana Inc. will post $11.55 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be issued a $0.40 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.64%. Humana’s payout ratio is presently 13.06%.
In other news, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the transaction, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider William Kevin Fleming sold 3,071 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was sold at an average price of $250.98, for a total value of $770,759.58. Following the completion of the transaction, the insider now directly owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,566 shares of company stock valued at $15,326,746. 0.80% of the stock is currently owned by insiders.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.